What to Expect from the ARPKD EL-PFDD Meeting
On August 29, 2023 the PKD Foundation will hold its first ever Externally Led Patient-focused Drug Development (EL-PFDD) Meeting on Autosomal Recessive PKD (ARPKD) and Congenital Hepatic Fibrosis (CHF). Should you attend the meeting? What should you expect? Get answers to these questions and more by attending our webinar on August 8!
Learn more about this meeting here.
Hyman, Phelps & McNamara
James has worked the last 15 years as a champion for the patient voice as part of the regulatory process. James previously worked at the FDA where he was a patient liaison, helping to incorporate the patient voice into medical product review across the FDA’s various medical product centers and review divisions. There, he helped to develop and launch the Patient-Focused Drug Development initiative.
Larry Bauer – Hyman, Phelps & McNamara
Larry worked at the NIH for 17 years in clinical research, followed by a position at the FDA as a Regulatory Scientist in the Center for Drug Evaluation and Research’s Rare Diseases Program, a group he co-founded and worked for 10 years, where he advanced rare disease drug development.